看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- Z( N* B% _, b* ?9 {& c0 X4 r
5 t$ J6 s) U, t- m
5 t F) k7 E. o; n+ k) Z
Currently available feasibility data for possible combination strategies. 6 w% d0 A3 { Z
————————————————————————————————1 _, p0 S! i" T- A' i) h+ d
Combination Feasibility according to preliminary data
- T1 \8 w) S9 I% g1 o) U——————————————————————————————————, G2 y7 ?, k" S" a
Bevacizumab + sorafenib Yes, reduced dose
2 b2 K7 C5 f3 t+ d( M& z/ B# L3 BBevacizumab + sunitinib† No . o4 U! t2 J0 ~* s
Bevacizumab + temsirolimus Yes % x2 w7 z7 [1 J W0 a
Bevacizumab + everolimus Yes
9 D/ U1 c, `6 K2 l) V! t0 @Sorafenib + sunitinib ? 6 Y% {4 g5 o4 ]+ X" T3 |
Sorafenib + temsirolimus Yes, reduced dose
; t- Y- X" W7 E8 N$ mSorafenib + everolimus Yes, reduced dose ' }8 u0 i* O$ l1 \3 N
Sunitinib + temsirolimus† No
% q2 G. g" q1 F2 I$ E& Q' e4 @! {Sunitinib + everolimus ? 9 o) a7 B3 n) n9 d' U- J3 I
Temsirolimus + everolimus ? 9 N$ A Z, V$ l# R$ ?+ {! S% Z7 G
————————————————————
5 z' v( @ [9 W5 L$ W( o2 L% N, k†Led to US FDA warning.
% R: q. k7 U5 B4 ?% ]?: As yet unattempted combination.
9 w) x! d- ^5 Q: M |